Actavis
Recent News About Actavis View More
-
Magistrate who oversaw discovery in Chicago's opioid lawsuit recuses himself, at city's request
Judge Kim's sister is a lawyer for pharma defendant, which lawyers for the city of Chicago said presents unavoidable conflict. The drug makers argued the recusal was unncessary, and will serve to only again "disrupt" the already lengthy court proceedings over the city's lawsuit. -
Two IL labor unions partner to sue opioid makers, distributors, promoters; Edelson firm to represent
Two unions have added their names to the long and growing list of organizations suing the makers and distributors of opioid painkillers. -
Class action suit says drug companies caused opioid crisis, heightened insurance costs
A Chicago class-action lawyer has filed a 97-page lawsuit in Chicago federal court against 13 drug companies and distributors, on behalf of a woman who alleges the companies promoted opioid use, knowing such painkillers were dangerously addictive, jacking up people's health insurance costs. -
Judge pauses Chicago opioid lawsuit; judges mull consolidating host of similar cases nationally
A federal judge has placed on hold the city of Chicago’s lawsuit accusing the makers of prescription painkillers like Oxycontin and Percocet – so-called “opioids” – of falsely marketing their drugs to doctors. defrauding City Hall and other employee health plan administrators, while giving time for a panel of federal judges to decide if the action should be consolidated with other similar lawsuits, brought by cities and others, now pending in other jurisdictions. -
Chicago given third try at pressing opioid deception fraud suit vs drugmakers
A Chicago federal judge is giving City Hall a third try to refine its opioid fraud lawsuit vs drugmakers. -
Judge tosses insurers' RICO class action vs testosterone drug makers, saying not specific enough
A federal judge has tossed, with leave to amend, the bulk of a federal racketeering and fraud class action brought by an Ohio-based health insurer against Abbvie and other makers of testosterone drugs, saying the insurer has not yet backed up with enough particularity its allegations the drugmakers invented the condition known as “low T,” and, through false marketing to doctors, patients and insurers alike, induced insurers and others to pay far more for the drugs to treat the condition.